These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 10855787)
1. Target antigens for prostate cancer immunotherapy. Saffran DC; Reiter RE; Jakobovits A; Witte ON Cancer Metastasis Rev; 1999; 18(4):437-49. PubMed ID: 10855787 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for prostate cancer. Fong L; Small EJ Semin Oncol; 2003 Oct; 30(5):649-58. PubMed ID: 14571412 [TBL] [Abstract][Full Text] [Related]
3. Advances in specific immunotherapy for prostate cancer. Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335 [TBL] [Abstract][Full Text] [Related]
4. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Zhang S; Zhang HS; Reuter VE; Slovin SF; Scher HI; Livingston PO Clin Cancer Res; 1998 Feb; 4(2):295-302. PubMed ID: 9516914 [TBL] [Abstract][Full Text] [Related]
5. Current immunotherapeutic strategies in prostate cancer. Grosso JF; Drake CG Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549 [TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer--focus on prostate-specific membrane antigen? Chang SS; Bander NH; Heston WD Curr Opin Urol; 1999 Sep; 9(5):391-5. PubMed ID: 10579076 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Waeckerle-Men Y; Uetz-von Allmen E; Fopp M; von Moos R; Böhme C; Schmid HP; Ackermann D; Cerny T; Ludewig B; Groettrup M; Gillessen S Cancer Immunol Immunother; 2006 Dec; 55(12):1524-33. PubMed ID: 16612599 [TBL] [Abstract][Full Text] [Related]
8. Prostate cancer: advances in immunotherapy. Hurwitz AA; Yanover P; Markowitz M; Allison JP; Kwon ED BioDrugs; 2003; 17(2):131-8. PubMed ID: 12641491 [TBL] [Abstract][Full Text] [Related]
9. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1. Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470 [TBL] [Abstract][Full Text] [Related]
10. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice. Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311 [TBL] [Abstract][Full Text] [Related]
11. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon. Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945 [TBL] [Abstract][Full Text] [Related]
12. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512 [TBL] [Abstract][Full Text] [Related]
13. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069 [TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for prostate cancer. Fong L; Small EJ Curr Oncol Rep; 2007 May; 9(3):226-33. PubMed ID: 17430695 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for prostate cancer. Fong L; Small EJ Curr Urol Rep; 2006 May; 7(3):239-46. PubMed ID: 16630528 [TBL] [Abstract][Full Text] [Related]
17. Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review. Khalili N; Keshavarz-Fathi M; Shahkarami S; Hirbod-Mobarakeh A; Rezaei N J Oncol Pharm Pract; 2019 Jun; 25(4):903-917. PubMed ID: 30348069 [TBL] [Abstract][Full Text] [Related]
18. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Hwang C; Sanda MG Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762 [TBL] [Abstract][Full Text] [Related]
19. Tumor vaccines for the management of prostate cancer. McNeel DG; Disis ML Arch Immunol Ther Exp (Warsz); 2000; 48(2):85-93. PubMed ID: 10807048 [TBL] [Abstract][Full Text] [Related]
20. Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer. Antonarakis ES Asian J Androl; 2012 Jul; 14(4):520-1. PubMed ID: 22580638 [No Abstract] [Full Text] [Related] [Next] [New Search]